Streetbeat News

Price Targets

RNAZ

HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on TransCode Therapeutics (NASDAQ:RNAZ) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:40 am

CAPR

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Capricor Therapeutics (NASDAQ:CAPR) and maintained an $18 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:39 am

MBIO

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Mustang Bio (NASDAQ:MBIO) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:35 am

HRTX

Needham analyst Serge Belanger has reiterated a 'Buy' rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:33 am

ROIV

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:31 am

DH

Needham analyst Ryan MacDonald has reiterated a 'Buy' rating on Definitive Healthcare (NASDAQ:DH) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:30 am

EMX

HC Wainwright & Co. analyst Heiko Ihle has reiterated a 'Buy' rating on EMX Royalty (AMEX:EMX) and maintained a price target of $4.75.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:29 am

USAS

HC Wainwright & Co. analyst Heiko Ihle has reiterated a 'Buy' rating on Americas Gold And Silver (AMEX:USAS) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:29 am

RVNC

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) and maintained a price target of $41.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:27 am

OTLK

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Outlook Therapeutics (NASDAQ:OTLK) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:27 am